Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

BACKGROUND: To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. METHODS: We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye clinic in Switzerland between January 1st and Dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Martin K., Reich, Oliver, Blozik, Eva, Faes, Livia, Bodmer, Nicolas S., Locher, Silvan, Thiel, Michael A., Rapold, Roland, Kuhn, Maximilian, Bachmann, Lucas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830340/
https://www.ncbi.nlm.nih.gov/pubmed/29486762
http://dx.doi.org/10.1186/s12886-018-0731-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830340/
https://www.ncbi.nlm.nih.gov/pubmed/29486762
http://dx.doi.org/10.1186/s12886-018-0731-4

Ejemplares similares